ipamorelin side effects clinical studies cjc-1295 ipamorelin human study CJC-1295/Ipamorelin Benefits, Side Effects, and Cost: The Complete Patient ipamorelin clinical trial safety adverse

GHRH plus GHRP-6 was administered together at 100mcg each

Landscapes Health & Medical Sciences (AREA) Life Sciences & Earth Sciences (AREA) Engineering & Computer Science (AREA) Biomedical Technology (AREA) Biotechnology (AREA) Chemical & Material Sciences (AREA) Organic Chemistry (AREA) Genetics & Genomics (AREA) Zoology (AREA) Bioinformatics & Cheminformatics (AREA) Wood Science & Technology (AREA) General Health & Medical Sciences (AREA) Biochemistry (AREA) General Engineering & Computer Science (AREA) Microbiology (AREA) Cell Biology (AREA) Biophysics (AREA) Molecular Biology (AREA) Medicinal Chemistry (AREA) Gastroenterology & Hepatology (AREA) Toxicology (AREA) Hematology (AREA) Proteomics, Peptides & Aminoacids (AREA) Physics & Mathematics (AREA) Analytical Chemistry (AREA) General Physics & Mathematics (AREA) Immunology (AREA) Pathology (AREA) Micro-Organisms Or Cultivation Processes Thereof (AREA) Peptides Or Proteins (AREA) US15/302,488 2014-04-10 2015-04-07 Compounded media powder formulation and method of preparation of liquid medium for cell culture Active 2035-11-20 US10227559B2 (en) Priority Applications (1) Applications Claiming Priority (3) Publications (2) Family ID=53055095 Family Applications (1) Country Status (14) Families Citing this family (9) Citations (17) Family Cites Families (5) 2015 2015-04-07 US US15/302,488 patent/US10227559B2/en active Active 2015-04-07 PE PE2016001936A patent/PE20161326A1/es not_active Application Discontinuation 2015-04-07 RU RU2016144057A patent/RU2016144057A/ru not_active Application Discontinuation 2015-04-07 MX MX2016013223A patent/MX2016013223A/es unknown 2015-04-07 CA CA2945390A patent/CA2945390A1/en not_active Abandoned 2015-04-07 SG SG11201608390SA patent/SG11201608390SA/en unknown 2015-04-07 AU AU2015243961A patent/AU2015243961A1/en not_active Abandoned 2015-04-07 KR KR1020167031066A patent/KR20160144429A/ko not_active Ceased 2015-04-07 WO PCT/US2015/024780 patent/WO2015157335A1/en not_active Ceased 2015-04-07 CN CN201580028914.1A patent/CN106459907B/zh not_active Expired - Fee Related 2015-04-07 EP EP15721063.4A patent/EP3129463B1/en active Active 2015-04-07 JP JP2016561351A patent/JP6665104B2/ja not_active Expired - Fee Related 2016 2016-10-06 IL IL248218A patent/IL248218A0/en unknown 2016-11-09 ZA ZA2016/07719A patent/ZA201607719B/en unknown Patent Citations (17) Non-Patent Citations (11) Also Published As Similar Documents Legal Events

Unlike some other GH-stimulating compounds, Ipamorelin triggers GH release without significantly raising cortisol or prolactin levels, making it a useful tool for studying isolated GH activity

Ipamorelin selectively activates ghrelin receptors without elevating cortisol